Effect of Topically Administered Prostamide and Prostaglandin Analogs on Central Corneal Thickness

Abstract

Abstract: : Purpose: To determine the effect of ocular treatment with topically administered prostamide or prostaglandin analogs on central corneal thickness (CCT). Methods: Retrospective analysis of pachymetry data of glaucomatous patients without previous ocular medication who underwent treatment with prostaglandin analogs or prostamides. Pachymetry was measured by means of ultrasound pachymetry (Compuscan P Ultrasonic Pachymeter System model UPC 1000 ). 24 patients were using latanoprost 0.005%, 17 patients were under treatment with travoprost 0.004%and 31 patients with bimatoprost 0.03%. Student t test was used to compare CCT values without medication (initial CCT) and after a period of 8±1 weeks of treatment (final CCT). Analysis of covariance (ANOVA) was used for comparison between groups. Results: Latanoprost group: mean initial CCT was 548.58±32.45µm and mean final CCT was 543.88±35.58µm (p<0.001) Travoprost group: 538.47±32.01µm initial CCT and 532.25±30.32µm final CCT (p<0.001) Bimatoprost group: 544.41±35.34µm initial CCT and 540.35±35.90µm final CCT (p<0.001) The level of CCT reduction was not different between groups (p=0.758). Conclusion: Central corneal thickness measured by ultrasound pachymetry decreases during treatment with topically administered prostamide or prostaglandin analogs.

Keywords: drug toxicity/drug effects • cornea: stroma and keratocytes